Rapid Micro Biosystems to Present at the H.C. Wainwright 27th Annual Global Investment Conference
RPID(NASDAQ:RPID) LEXINGTON, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will present at the H.C.Wainwright 27th Annual Global Investment Conference in New York, NY.
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
RPIDLEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025.
Rapid Micro Biosystems Enters into Five-Year, $45 Million Term Loan Facility with Trinity Capital Inc.
RPIDLEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company” or “Rapid Micro”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. (Nasdaq: TRIN) (“Trinity Capital”).
Rapid Micro Biosystems Reaffirms FY2025 Revenue Guidance Of $32M vs $32.55M Est.
RPIDRapid Micro Biosystems Q1 EPS $(0.26) Beats $(0.27) Estimate, Sales $7.21M Beat $6.60M Estimate
RPIDRapid Micro Biosystems's Earnings Outlook
RPIDRapid Micro Biosystems Sees FY2025 Sales $32.000M vs $32.90M Est
RPIDRapid Micro Biosystems Q4 EPS $(0.22) Beats $(0.23) Estimate, Sales $8.22M Beat $7.80M Estimate
RPIDRapid Micro Biosystems Announced 5-Year Distribution Deal With Merck KGaA's Life Science Unit; MilliporeSigma Gains Co-Exclusive Rights To Sell Growth Direct Systems; Collaboration To Cut Costs And Expand Margins; Additional Joint Development Opportuniti
RPIDKeybanc Initiates Coverage On Rapid Micro Biosystems with Overweight Rating, Announces Price Target of $8
RPIDRapid Micro Biosystems Sees Q4 Revenue ~$8.2M Vs $7.60M Est.
RPIDRapid Micro Biosystems Reaffirms FY2024 total revenue guidance of at least $27M (Est $26.6M)
RPIDRapid Micro Biosystems Q3 2024 GAAP EPS $(0.26) Beats $(0.28) Estimate, Sales $7.604M Beat $6.550M Estimate
RPID